TG Therapeutics (FRA:NKB2) Institutional Ownership: 48.04% (As of Jul. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NKB2 TG Therapeutics Inc FRA:NKB2
80 GF Score
Price €48.70
GF Value €49.62
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is TG Therapeutics Institutional Ownership?

TG Therapeutics FRA:NKB2 +1.04% 80 Institutional Ownership is 48.04% as of Jul. 28, 2026. GuruFocus rates FRA:NKB2 with a GF Score™ of 80/100 and a GF Value™ of €49.62 (Fairly Valued). The stock has 8 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, TG Therapeutics's institutional ownership is 48.04%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, TG Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, TG Therapeutics's Float Percentage Of Total Shares Outstanding is 69.19%.

TG Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for TG Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TG Therapeutics Institutional Ownership Chart

TG Therapeutics Historical Data

The historical data trend for TG Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 45.41 44.25 44.78 45.79 45.94 45.26 47.44 47.93 47.73 48.04
FRA:NKB2
80GF Score
TG Therapeutics Inc FRA:NKB2
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TG Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 48.04% mean?
TG Therapeutics (FRA:NKB2) has a Institutional Ownership of 48.04% as of Jul. 28, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on TG Therapeutics and its competitors.
Is TG Therapeutics' Institutional Ownership too high?
TG Therapeutics' current Institutional Ownership is 48.04%. Overall, TG Therapeutics has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TG Therapeutics' Institutional Ownership compare to PTGX and CRNX?
TG Therapeutics' Institutional Ownership of 48.04% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on TG Therapeutics and its competitors. TG Therapeutics's current Institutional Ownership is 48.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TG Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TG Therapeutics (FRA:NKB2) is currently considered Fairly Valued. The stock's GF Value™ is €49.62, compared to a current price of €48.70 — trading 1.9% below its estimated fair value. The current Institutional Ownership is 48.04%. TG Therapeutics' overall GF Score™ is 80/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For TG Therapeutics (FRA:NKB2), the current Institutional Ownership is 48.04% as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TG Therapeutics (FRA:NKB2) Overvalued in 2026?

Based on GuruFocus' analysis, TG Therapeutics stock appears to be undervalued. The current stock price of €48.70 is trading 1.9% below its estimated GF Value™ of €49.62. GuruFocus considers TG Therapeutics to be Fairly Valued.

Key valuation signals for FRA:NKB2:

  • Institutional Ownership: 48.04%
  • GF Value™: €49.62 vs. price of €48.70 (1.9% below fair value)
  • GF Score™: 80/100 with 8 warning signs

No single metric tells the full story. See the FRA:NKB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TG Therapeutics Business Description

Other Exchanges TGTX:USA1TGTX:Italy
Address 3020 Carrington Mill Boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
80GF Score

Get the complete analysis for FRA:NKB2

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€48.70
Price
€49.62
GF Value